Shire PLC (SHPG) Position Cut by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its position in Shire PLC (NASDAQ:SHPG) by 9.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,192 shares of the biopharmaceutical company’s stock after selling 454 shares during the period. Janney Montgomery Scott LLC’s holdings in Shire were worth $708,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in SHPG. Signaturefd LLC raised its holdings in shares of Shire by 18.4% during the first quarter. Signaturefd LLC now owns 2,165 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 336 shares during the period. United Capital Financial Advisers LLC raised its holdings in shares of Shire by 7.2% during the first quarter. United Capital Financial Advisers LLC now owns 5,946 shares of the biopharmaceutical company’s stock valued at $888,000 after purchasing an additional 401 shares during the period. Usca Ria LLC raised its holdings in shares of Shire by 2.4% during the first quarter. Usca Ria LLC now owns 19,828 shares of the biopharmaceutical company’s stock valued at $2,962,000 after purchasing an additional 467 shares during the period. Mariner LLC raised its holdings in shares of Shire by 27.3% during the first quarter. Mariner LLC now owns 2,256 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 484 shares during the period. Finally, Israel Discount Bank of New York raised its holdings in shares of Shire by 11.9% during the first quarter. Israel Discount Bank of New York now owns 4,734 shares of the biopharmaceutical company’s stock valued at $708,000 after purchasing an additional 504 shares during the period. Institutional investors and hedge funds own 17.61% of the company’s stock.

SHPG opened at $169.13 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.45. Shire PLC has a fifty-two week low of $123.73 and a fifty-two week high of $177.51. The stock has a market capitalization of $52.16 billion, a P/E ratio of 11.16, a price-to-earnings-growth ratio of 1.52 and a beta of 1.19.



Shire (NASDAQ:SHPG) last posted its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.67 by $0.21. Shire had a net margin of 31.06% and a return on equity of 13.22%. The company had revenue of $3.92 billion for the quarter. During the same quarter in the prior year, the company earned $3.73 EPS. The company’s revenue was up 4.6% on a year-over-year basis. equities analysts forecast that Shire PLC will post 15.29 EPS for the current fiscal year.

Several equities analysts have recently weighed in on SHPG shares. Royal Bank of Canada set a $186.00 price objective on shares of Shire and gave the company a “buy” rating in a report on Sunday, April 22nd. B. Riley upped their price objective on shares of Shire to $200.00 and gave the company a “buy” rating in a report on Thursday, April 19th. Zacks Investment Research upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Monday, April 23rd. ValuEngine lowered shares of Shire from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, BTIG Research reiterated a “buy” rating and set a $195.00 price objective on shares of Shire in a report on Sunday, April 29th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $200.75.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Featured Story: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply